| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7fe4857039551c40a688cfffcafa2937 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y603-05005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-90 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-30 |
| filingDate |
1993-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1998-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f86dae0eb1a14beb0970f9da0ad30658
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3626ff165701e0dfaf29673d6fd167eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc359344028713cb8bf0a30e53ba61b6 |
| publicationDate |
1998-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5849573-A |
| titleOfInvention |
Nucleotide sequence encoding carbamoyl phosphate synthetase II |
| abstract |
PCT No. PCT/AU93/00617 Sec. 371 Date Jul. 6, 1995 Sec. 102(e) Date Jul. 6, 1995 PCT Filed Dec. 2, 1993 PCT Pub. No. WO94/12643 PCT Pub. Date Jun. 9, 1994The present invention provides a nucleotide sequence encoding carbamoyl phosphate synthetase II of Plasmodium falciparum. Carbamoyl phosphate synthetase II catalyses the first committed and rate-limiting step in the de novo pyrimidine biosynthetic pathway. P. falciparum relies exclusively on pyrimidine synthesis de novo because of its inability to salvage pyrimidines. Mature human red blood cells, however, have no recognised requirement for a pyrimidine nucleotide. Accordingly, this enzyme represents a prime chemotherapeutic locus. The present invention relates to the use of the sequence encoding carbamoyl phosphate synthetase II in the recombinant production of carbamoyl phosphate synthetase II and to antisense molecules, ribozymes and other gene inactivation agents designed from this sequence. |
| priorityDate |
1992-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |